Document_And_Entity_Informatio
Document And Entity Information | 3 Months Ended | |
Sep. 30, 2013 | Nov. 08, 2013 | |
Document And Entity Information [Abstract] | ' | ' |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 30-Sep-13 | ' |
Document Fiscal Year Focus | '2014 | ' |
Document Fiscal Period Focus | 'Q1 | ' |
Entity Registrant Name | 'Electromed, Inc. | ' |
Entity Central Index Key | '0001488917 | ' |
Current Fiscal Year End Date | '--06-30 | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Common Stock, Shares Outstanding | ' | 8,114,252 |
Condensed_Consolidated_Balance
Condensed Consolidated Balance Sheets (USD $) | Sep. 30, 2013 | Jun. 30, 2013 |
Current Assets | ' | ' |
Cash and cash equivalents | $1,077,382 | $503,564 |
Accounts receivable (net of allowances for doubtful accounts of $45,000) | 7,989,355 | 9,014,043 |
Inventories | 1,432,222 | 1,379,594 |
Prepaid expenses and other current assets | 460,914 | 428,843 |
Income taxes receivable | 779,644 | 538,285 |
Deferred income taxes | 557,000 | 557,000 |
Total current assets | 12,296,517 | 12,421,329 |
Property and equipment, net | 3,761,298 | 3,743,675 |
Finite-life intangible assets, net net | 1,049,115 | 1,080,734 |
Other assets | 304,605 | 310,089 |
Total assets | 17,411,535 | 17,555,827 |
Current Liabilities | ' | ' |
Current maturities of long-term debt | 52,662 | 57,540 |
Accounts payable | 950,152 | 643,681 |
Accrued compensation | 334,553 | 565,023 |
Warranty reserve | 680,000 | 680,000 |
Other accrued liabilities | 342,169 | 247,267 |
Total current liabilities | 2,359,536 | 2,193,511 |
Long-term debt, less current maturities | 1,318,083 | 1,332,455 |
Deferred income taxes | 103,000 | 103,000 |
Total liabilities | 3,780,619 | 3,628,966 |
Commitments and Contingencies | ' | ' |
Equity | ' | ' |
Common stock, $0.01 par value; authorized: 13,000,000 shares; shares, issued and outstanding: 8,114,252 | 81,143 | 81,143 |
Additional paid-in capital | 13,174,398 | 13,134,938 |
Retained earnings | 375,375 | 710,780 |
Total equity | 13,630,916 | 13,926,861 |
Total liabilities and equity | $17,411,535 | $17,555,827 |
Condensed_Consolidated_Balance1
Condensed Consolidated Balance Sheets (Parenthetical) (USD $) | Sep. 30, 2013 | Jun. 30, 2013 |
Condensed Consolidated Balance Sheets [Abstract] | ' | ' |
Accounts receivable, allowance for doubtful accounts | $45,000 | $45,000 |
Common stock, par value | $0.01 | $0.01 |
Common stock, shares authorized | 13,000,000 | 13,000,000 |
Common stock, shares issued | 8,114,252 | 8,114,252 |
Common stock, shares outstanding | 8,114,252 | 8,114,252 |
Condensed_Consolidated_Stateme
Condensed Consolidated Statements Of Operations (USD $) | 3 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Condensed Consolidated Statements Of Operations [Abstract] | ' | ' |
Net revenues | $3,418,178 | $4,031,286 |
Cost of revenues | 1,062,346 | 1,210,452 |
Gross profit | 2,355,832 | 2,820,834 |
Operating expenses | ' | ' |
Selling, general and administrative | 2,723,927 | 2,816,015 |
Research and development | 209,108 | 101,189 |
Total operating expenses | 2,933,035 | 2,917,204 |
Operating loss | -577,203 | -96,370 |
Interest expense, net of interest income of $7,398 and $4,348 respectively | 15,202 | 36,738 |
Net loss before income taxes | -592,405 | -133,108 |
Income tax benefit | 257,000 | 62,000 |
Net loss | ($335,405) | ($71,108) |
Loss per share: | ' | ' |
Basic and diluted | ($0.04) | ($0.01) |
Weighted-average common shares outstanding: | ' | ' |
Basic | 8,114,252 | 8,114,252 |
Diluted | 8,114,252 | 8,114,252 |
Condensed_Consolidated_Stateme1
Condensed Consolidated Statements Of Operations (Parenthetical) (USD $) | 3 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Condensed Consolidated Statements Of Operations [Abstract] | ' | ' |
Interest income | $7,398 | $4,348 |
Condensed_Consolidated_Stateme2
Condensed Consolidated Statements Of Cash Flows (USD $) | 3 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Cash Flows From Operating Activities | ' | ' |
Net loss | ($335,405) | ($71,108) |
Adjustments to reconcile net loss to net cash provided by operating activities: | ' | ' |
Depreciation | 122,923 | 114,979 |
Amortization of finite-life intangible assets | 31,619 | 33,969 |
Amortization of debt issuance costs | 2,314 | 3,363 |
Share-based compensation expense | 39,460 | 41,317 |
Loss on disposal of property and equipment | 18,134 | 3,915 |
Changes in operating assets and liabilities: | ' | ' |
Accounts receivable | 1,024,688 | 435,371 |
Inventories | -52,628 | 87,140 |
Prepaid expenses and other assets | -270,260 | -187,706 |
Accounts payable and accrued liabilities | 161,138 | -347,226 |
Net cash provided by operating activities | 741,983 | 114,014 |
Cash Flows From Investing Activities | ' | ' |
Expenditures for property and equipment | -148,915 | -197,020 |
Expenditures for finite-life intangible assets | ' | -27,073 |
Net cash used in investing activities | -148,915 | -224,093 |
Cash Flows From Financing Activities | ' | ' |
Principal payments on long-term debt including capital lease obligations | -19,250 | -109,801 |
Net increase (decrease) in cash and cash equivalents | 573,818 | -219,880 |
Cash and cash equivalents | ' | ' |
Beginning of period | 503,564 | 1,702,435 |
End of period | $1,077,382 | $1,482,555 |
Interim_Financial_Reporting
Interim Financial Reporting | 3 Months Ended | |
Sep. 30, 2013 | ||
Interim Financial Reporting [Abstract] | ' | |
Interim Financial Reporting | ' | |
Note 1. | Interim Financial Reporting | |
Basis of presentation: Electromed, Inc. (the "Company") develops, manufactures and markets innovative airway clearance products which apply High Frequency Chest Wall Oscillation ("HFCWO") therapy in pulmonary care for patients of all ages. The Company markets its products in the United States to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $149,000 and $109,000 for the three months ended September 30, 2013 and 2012, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment. | ||
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations as required by Regulation S-X, Rule 10-01. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the consolidated financial statements included in the Company's annual report on Form 10-K for the year ended June 30, 2013. | ||
Principles of consolidation: The accompanying condensed consolidated financial statements include the accounts of Electromed, Inc. and its subsidiary, Electromed Financial, LLC. Operating activities and net assets in Electromed Financial, LLC were insignificant as of and for the three months ended September 30, 2013 and the year ended June 30, 2013. | ||
Liquidity: For the three months ended September 30, 2013, the Company incurred a net loss of approximately $335,000, primarily as a result of a decrease in domestic home care revenues. Cash provided by operating activities was $742,000 for the three months ended September 30, 2013. The principal sources of liquidity in the future are expected to be cash flows from operations and availability on our line of credit. In order to operate profitably in the future, the Company must increase its revenue. | ||
The Company's ability to generate sufficient cash flows in fiscal 2014 could be negatively impacted by the business challenges in reimbursement from third party payers. There continues to be downward pressure on pricing and added administrative procedures implemented by third party payers in the insurance claims process which has lengthened the approval process compared with the prior year. In fiscal 2013, one of the largest domestic third party payers decentralized its contracting process. As a result, the decentralization has required significantly more administrative efforts on the part of the Company to complete the necessary contracts to maintain our national coverage with that payer. Certain contracts were resolved during fiscal 2013, although the final completion of this process has extended into fiscal year 2014. The challenges the Company currently faces could result in future noncompliance with the covenants contained within the Company's credit facility. Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of the Company's indebtedness or preventing access to additional funds under the credit facility, or requiring prepayment of outstanding indebtedness under the credit facility. If the maturity of the indebtedness is accelerated, or the Company is unable to renew the line of credit, sufficient cash resources to satisfy the debt obligations may not be available and the Company may not be able to continue operations as planned. The indebtedness under the credit agreement is secured by a security interest in substantially all tangible and intangible assets of the Company. If the Company is unable to repay such indebtedness, the bank could foreclose on these assets. | ||
A summary of the Company's significant accounting policies follows: | ||
Use of estimates: Management uses estimates and assumptions in preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve. | ||
Net loss per common share: Net loss is presented on a per share basis for both basic and diluted common shares. Basic net loss per common share is computed using the weighted average number of common shares outstanding during the period. The diluted net loss per common share calculation assumes that all stock warrants were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents of 614,900 and 599,900 were excluded from the calculation of diluted earnings per share for the three months ended September, 2013 and 2012, respectively, as their impact was antidilutive. | ||
Inventories
Inventories | 3 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Inventories [Abstract] | ' | |||||||
Inventories | ' | |||||||
Note 2. | Inventories | |||||||
The components of inventory were approximately as follows: | ||||||||
September 30, | June 30, | |||||||
2013 | 2013 | |||||||
Parts inventory | $ | 1,050,000 | $ | 951,000 | ||||
Work in process | 231,000 | 196,000 | ||||||
Finished goods | 181,000 | 263,000 | ||||||
Less: Reserve for obsolescence | (30,000 | ) | (30,000 | ) | ||||
Total | $ | 1,432,000 | $ | 1,380,000 | ||||
FiniteLife_Intangible_Assets
Finite-Life Intangible Assets | 3 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Finite-Life Intangible Assets [Abstract] | ' | |||||||
Finite-Life Intangible Assets | ' | |||||||
Note 3. | Finite-Life Intangible Assets | |||||||
The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. Accumulated amortization was $511,000 and $479,000 at September 30, 2013 and June 30, 2013, respectively. | ||||||||
The activity and balances of finite-life intangible assets were approximately as follows: | ||||||||
Three Months | Year | |||||||
Ended | Ended | |||||||
September 30, | June 30, | |||||||
2013 | 2013 | |||||||
Balance, beginning | $ | 1,081,000 | $ | 1,174,000 | ||||
Additions | — | 37,000 | ||||||
Amortization expense | (32,000 | ) | (130,000 | ) | ||||
Balance, ending | $ | 1,049,000 | $ | 1,081,000 | ||||
Warranty_Liability
Warranty Liability | 3 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Warranty Liability [Abstract] | ' | |||||||
Warranty Liability | ' | |||||||
Note 4. | Warranty Liability | |||||||
The Company provides a lifetime warranty on its products to the prescribed patient for sales within the United States and a three-year warranty for all institutional sales and sales to individuals outside the United States. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company's warranty liability include the number of units shipped, historical and anticipated rates of warranty claims, and cost per claim. The Company periodically assesses the adequacy of its recorded warranty liability and adjusts the amounts as necessary. | ||||||||
Changes in the Company's warranty liability were approximately as follows: | ||||||||
Three Months | Year Ended | |||||||
Ended | June 30, | |||||||
September 30, | 2013 | |||||||
2013 | ||||||||
Balance warranty reserve | $ | 680,000 | $ | 610,000 | ||||
Accrual for products sold | 43,000 | 232,000 | ||||||
Expenditures and costs incurred for warranty claims | (43,000 | ) | (162,000 | ) | ||||
Ending warranty reserve | $ | 680,000 | $ | 680,000 |
Income_Taxes
Income Taxes | 3 Months Ended | |
Sep. 30, 2013 | ||
Income Taxes [Abstract] | ' | |
Income Taxes | ' | |
Note 5. | Income Taxes | |
On a quarterly basis, the Company estimates what its effective tax rate will be for the full fiscal year and records a quarterly income tax provision (benefit) based on the anticipated rate. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The effective tax rate for the three months ended September 30, 2013 and 2012 was 43.4% and 46.6%, respectively. | ||
Financing_Arrangements
Financing Arrangements | 3 Months Ended | |
Sep. 30, 2013 | ||
Financing Arrangements [Abstract] | ' | |
Financing Arrangements | ' | |
Note 6. | Financing Arrangements | |
The Company has a credit facility that provides for term loans and a revolving line of credit of $2,250,000, as of September 30, 2013. The line of credit expires on December 31, 2013, if not renewed. Advances are due at the expiration date and are secured by substantially all Company assets. Interest on advances accrues at LIBOR plus 3.50% (3.75% at September 30, 2013) and is payable monthly. The amount available for borrowing is limited to 60% of eligible accounts receivable. As of September 30, 2013, the Company had net unused availability of $2,250,000 under the line of credit. The Company's credit facility contains certain financial and nonfinancial covenants and restricts the payment of dividends. The Company is working with the bank to renew its line of credit. Given the Company's ability to service its debt and its past relationship with its lender, the Company believes that it will be able to successfully renew the line of credit. | ||
Commitments_And_Contingencies
Commitments And Contingencies | 3 Months Ended | |
Sep. 30, 2013 | ||
Commitments And Contingencies [Abstract] | ' | |
Commitments And Contingencies | ' | |
Note 7. | Commitments and Contingencies | |
The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures its business risks where possible to mitigate the financial impact of individual claims, and establishes reserves for an estimate of any probable cost of settlement or other disposition. | ||
Related_Parties
Related Parties | 3 Months Ended | |
Sep. 30, 2013 | ||
Related Parties [Abstract] | ' | |
Related Parties | ' | |
Note 8. | Related Parties | |
The Company uses a parts supplier whose founder and president is a director of the Company. For the three months ended September 30, 2013 and 2012, the Company made payments to the supplier of approximately $14,000 and $101,000, respectively. | ||
Interim_Financial_Reporting_Po
Interim Financial Reporting (Policy) | 3 Months Ended |
Sep. 30, 2013 | |
Interim Financial Reporting [Abstract] | ' |
Nature Of Business | ' |
Electromed, Inc. (the "Company") develops, manufactures and markets innovative airway clearance products which apply High Frequency Chest Wall Oscillation ("HFCWO") therapy in pulmonary care for patients of all ages. The Company markets its products in the United States to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. International sales were approximately $149,000 and $109,000 for the three months ended September 30, 2013 and 2012, respectively. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment. | |
Basis Of Presentation | ' |
The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company's financial position and results of operations as required by Regulation S-X, Rule 10-01. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the consolidated financial statements included in the Company's annual report on Form 10-K for the year ended June 30, 2013. | |
Principles Of Consolidation | ' |
Principles of consolidation: The accompanying condensed consolidated financial statements include the accounts of Electromed, Inc. and its subsidiary, Electromed Financial, LLC. Operating activities and net assets in Electromed Financial, LLC were insignificant as of and for the three months ended September 30, 2013 and the year ended June 30, 2013. | |
Liquidity | ' |
Liquidity: For the three months ended September 30, 2013, the Company incurred a net loss of approximately $335,000, primarily as a result of a decrease in domestic home care revenues. Cash provided by operating activities was $742,000 for the three months ended September 30, 2013. The principal sources of liquidity in the future are expected to be cash flows from operations and availability on our line of credit. In order to operate profitably in the future, the Company must increase its revenue. | |
The Company's ability to generate sufficient cash flows in fiscal 2014 could be negatively impacted by the business challenges in reimbursement from third party payers. There continues to be downward pressure on pricing and added administrative procedures implemented by third party payers in the insurance claims process which has lengthened the approval process compared with the prior year. In fiscal 2013, one of the largest domestic third party payers decentralized its contracting process. As a result, the decentralization has required significantly more administrative efforts on the part of the Company to complete the necessary contracts to maintain our national coverage with that payer. Certain contracts were resolved during fiscal 2013, although the final completion of this process has extended into fiscal year 2014. The challenges the Company currently faces could result in future noncompliance with the covenants contained within the Company's credit facility. Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of the Company's indebtedness or preventing access to additional funds under the credit facility, or requiring prepayment of outstanding indebtedness under the credit facility. If the maturity of the indebtedness is accelerated, or the Company is unable to renew the line of credit, sufficient cash resources to satisfy the debt obligations may not be available and the Company may not be able to continue operations as planned. The indebtedness under the credit agreement is secured by a security interest in substantially all tangible and intangible assets of the Company. If the Company is unable to repay such indebtedness, the bank could foreclose on these assets. | |
Use Of Estimates | ' |
Use of estimates: Management uses estimates and assumptions in preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include revenue recognition and the related estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence, share-based compensation, income taxes and the warranty reserve. | |
Net Loss Per Common Share | ' |
Net loss per common share: Net loss is presented on a per share basis for both basic and diluted common shares. Basic net loss per common share is computed using the weighted average number of common shares outstanding during the period. The diluted net loss per common share calculation assumes that all stock warrants were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. Common stock equivalents of 614,900 and 599,900 were excluded from the calculation of diluted earnings per share for the three months ended September, 2013 and 2012, respectively, as their impact was antidilutive. | |
Inventories_Tables
Inventories (Tables) | 3 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Inventories [Abstract] | ' | |||||||
Schedule Of Components Of Inventory | ' | |||||||
September 30, | June 30, | |||||||
2013 | 2013 | |||||||
Parts inventory | $ | 1,050,000 | $ | 951,000 | ||||
Work in process | 231,000 | 196,000 | ||||||
Finished goods | 181,000 | 263,000 | ||||||
Less: Reserve for obsolescence | (30,000 | ) | (30,000 | ) | ||||
Total | $ | 1,432,000 | $ | 1,380,000 |
FiniteLife_Intangible_Assets_T
Finite-Life Intangible Assets (Tables) | 3 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Finite-Life Intangible Assets [Abstract] | ' | |||||||
Schedule Of Finite-Life Intangible Assets | ' | |||||||
Three Months | Year | |||||||
Ended | Ended | |||||||
September 30, | June 30, | |||||||
2013 | 2013 | |||||||
Balance, beginning | $ | 1,081,000 | $ | 1,174,000 | ||||
Additions | — | 37,000 | ||||||
Amortization expense | (32,000 | ) | (130,000 | ) | ||||
Balance, ending | $ | 1,049,000 | $ | 1,081,000 |
Warranty_Liability_Tables
Warranty Liability (Tables) | 3 Months Ended | |||||||
Sep. 30, 2013 | ||||||||
Warranty Liability [Abstract] | ' | |||||||
Schedule Of Warranty Liability | ' | |||||||
Three Months | Year Ended | |||||||
Ended | June 30, | |||||||
September 30, | 2013 | |||||||
2013 | ||||||||
Balance warranty reserve | $ | 680,000 | $ | 610,000 | ||||
Accrual for products sold | 43,000 | 232,000 | ||||||
Expenditures and costs incurred for warranty claims | (43,000 | ) | (162,000 | ) | ||||
Ending warranty reserve | $ | 680,000 | $ | 680,000 |
Interim_Financial_Reporting_De
Interim Financial Reporting (Details) (USD $) | 3 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Sales | $3,418,178 | $4,031,286 |
Net income (loss) | -335,405 | -71,108 |
Cash provided (used) by operating activities | 741,983 | 114,014 |
Common stock equivalents excluded from calculation of diluted earnings per share | 614,900 | 599,900 |
International [Member] | ' | ' |
Sales | $149,000 | $109,000 |
Inventories_Details
Inventories (Details) (USD $) | Sep. 30, 2013 | Jun. 30, 2013 |
Inventories [Abstract] | ' | ' |
Parts inventory | $1,050,000 | $951,000 |
Work in process | 231,000 | 196,000 |
Finished goods | 181,000 | 263,000 |
Less: Reserve for obsolescence | -30,000 | -30,000 |
Total | $1,432,222 | $1,379,594 |
FiniteLife_Intangible_Assets_N
Finite-Life Intangible Assets (Narrative) (Details) (USD $) | Sep. 30, 2013 | Jun. 30, 2013 | Sep. 30, 2013 | Sep. 30, 2013 |
Patents [Member] | Trademarks [Member] | |||
Finite-Lived Intangible Assets [Line Items] | ' | ' | ' | ' |
Estimated useful life | ' | ' | '15 years | '12 years |
Accumulated amortization | $511,000 | $479,000 | ' | ' |
FiniteLife_Intangible_Assets_S
Finite-Life Intangible Assets (Schedule Of Finite-Life Intangible Assets) (Details) (USD $) | 3 Months Ended | 12 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | Jun. 30, 2013 | |
Finite-Life Intangible Assets [Abstract] | ' | ' | ' |
Balance, beginning | $1,080,734 | $1,174,000 | $1,174,000 |
Additions | ' | ' | 37,000 |
Amortization expense | -31,619 | -33,969 | -130,000 |
Balance, ending | $1,049,115 | ' | $1,080,734 |
Warranty_Liability_Narrative_D
Warranty Liability (Narrative) (Details) (Outside United States [Member]) | 3 Months Ended |
Sep. 30, 2013 | |
Outside United States [Member] | ' |
Warranty Liability [Line Items] | ' |
Warranty term | '3 years |
Warranty_Liability_Schedule_Of
Warranty Liability (Schedule Of Warranty Liability) (Details) (USD $) | 3 Months Ended | 12 Months Ended |
Sep. 30, 2013 | Jun. 30, 2013 | |
Warranty Liability [Abstract] | ' | ' |
Beginning warranty reserve | $680,000 | $610,000 |
Accrual for products sold | 43,000 | 232,000 |
Expenditures and costs incurred for warranty claims | -43,000 | -162,000 |
Ending warranty reserve | $680,000 | $680,000 |
Income_Taxes_Details
Income Taxes (Details) | 3 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Income Taxes [Abstract] | ' | ' |
Effective tax rate | 43.40% | 46.60% |
Financing_Arrangements_Details
Financing Arrangements (Details) (USD $) | 3 Months Ended |
Sep. 30, 2013 | |
Financing Arrangements [Abstract] | ' |
Maximum borrowing capacity | $2,250,000 |
Credit facility expiration date | 31-Dec-13 |
Amount added to LIBOR for interest rate | 3.50% |
Effective interest rate including LIBOR | 3.75% |
Borrowing restriction, percent of eligible accounts receivable | 60.00% |
Net unused availability | $2,250,000 |
Related_Parties_Details
Related Parties (Details) (USD $) | 3 Months Ended | |
Sep. 30, 2013 | Sep. 30, 2012 | |
Related Party Transaction [Line Items] | ' | ' |
Payments to related party parts supplier | $14,000 | $101,000 |
Member Of Electromed's Board Of Directors [Member] | ' | ' |
Related Party Transaction [Line Items] | ' | ' |
Number of related parties | 1 | ' |